Although small cell lung cancer (SCLC) responds dramatically to initial platinum-based chemotherapy, recurrences are nearly universal. The addition of atezolizumab, an immune checkpoint inhibitor, to front-line chemotherapy has recently demonstrated an improvement in overall survival (OS) in extensive stage SCLC (ES-SCLC). Subsequent lines of therapies are associated with modest efficacy in patients with relapsed disease, and the median overall survival is still 12 to 13 months at best.
Cirtuvivint is a small molecule inhibitor of the CDC2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs); inhibiting CLKs and DYRKs has been shown in preclinical models to cause tumor growth inhibition and sensitize cancer cells to cytotoxic chemotherapy.
This study is testing the hypothesis that adding cirtuvivint to chemotherapy in patients with relapsed SCLC will be well tolerated and improve the response rate and progression-free survival (PFS).

开始日期2025-12-31

申办/合作机构

Washington University School of Medicine

[+1]

NCT06856499

/ Not yet recruiting临床1期IIT

Phase I Evaluation of Combination CLK/DYRK (Cirtuvivint) Inhibition With PARP Inhibition (Olaparib) in BRCA/HRD Platinum Resistant Ovarian Cancer

The purpose of this study is to learn about the safety and tolerability of Cirtuvivint in combination with Olaparib in platinum resistant ovarian cancer. The study also aims to determine the recommended dose of the combination therapy.
If a participant is a good fit for the study, and they enroll in the study, they will:
* Visit the clinic often at the beginning of the study for physical exams, blood draws, vital signs, and other study and routine care procedures. After the first two months participants will visit the clinic every 28 days.
* Take the study medications, Cirtuvivint and Olaparib. Participants will take Olaparib every day. Participants will either take Cirtuvivint 5 days per week or 2 days per week.

开始日期2025-12-01

申办/合作机构

University of Colorado Denver

[+2]

NCT06484062

/ Recruiting临床1期IIT

A Phase I Study Evaluating the Safety of Cirtuvivint as Monotherapy and in Combination With ASTX727 in Patients With Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)

This phase I trial tests the safety, side effects, and best dose of SM08502 (cirtuvivint) alone and in combination with ASTX727 in treating patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Cirtuvivint may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. ASTX727 is a combination of two drugs, decitabine and cedazuridine. Decitabine is in a class of medications called hypomethylation agents. It works by helping the bone marrow produce normal blood cells and by killing abnormal cells in the bone marrow. Cedazuridine is in a class of medications called cytidine deaminase inhibitors. It prevents the breakdown of decitabine, making it more available in the body so that decitabine will have a greater effect. Giving cirtuvivint alone or in combination with ASTX727 may be safe, tolerable, and/or effective in treating patients with AML and MDS.

开始日期2025-12-15

申办/合作机构

National Cancer Institute

100 项与 Cirtuvivint 相关的临床结果

登录后查看更多信息

100 项与 Cirtuvivint 相关的转化医学

登录后查看更多信息

100 项与 Cirtuvivint 相关的专利（医药）

登录后查看更多信息

项与 Cirtuvivint 相关的文献（医药）

2025-12-01·CANCER CHEMOTHERAPY AND PHARMACOLOGY

RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids

Article

作者: Coussens, Nathan P ; Doroshow, James H ; Silvers, Thomas ; Gore, Steven D ; Jones, Eric ; Teicher, Beverly A ; Dexheimer, Thomas S ; Kunkel, Mark

Abstract:

Purpose:

The alternative splicing of mRNA precursors allows one gene to yield multiple proteins with distinct functions. CDC-like kinases serve as pivotal regulators of alternative splicing. Control of protein expression also occurs at the level of DNA through histone methylation and demethylation. We investigated the activity of two CLK inhibitors, cirtuvivint and CC-671, and the LSD1 inhibitor iadademstat alone and in combination with anticancer drugs or investigational agents.

Methods:

Well-characterized patient-derived cancer cell lines from the PDMR (https://pdmr.cancer.gov/models/database.htm) were used along with standard human cancer cell lines. Multi-cell type-tumor spheroids were grown from a ratio of 6:2.5:1.5 malignant cells, endothelial cells, and mesenchymal stem cells. Following three days of growth, the spheroids were exposed to the single agents or combinations at concentrations up to the clinical Cmax value for each agent, if known. After seven days of exposure, cell viability was assessed using the CellTiter-Glo 3D assay and spheroid volume was assessed by bright field imaging.

Results:

Several of the targeted oncology drugs exhibited additive and greater-than-additive cytotoxicity when combined with a CLK inhibitor, or the LSD1 inhibitor. These agents included the XPO1 inhibitor, eltanexor, and the KRAS G12D specific inhibitor MRTX-1133 which had activity in tumor lines harboring the KRAS G12D mutation. LSD1 inhibition was effective with ubiquitin proteasome pathway inhibitors. Conclusion: These findings may provide guidance for development of clinical trial combination regimens including cirtuvivint, CC-671 or iadademstat. Full data sets are available on PubChem.

2025-02-01·Molecular Oncology

Targeting the CLK2/SRSF9 splicing axis in prostate cancer leads to decreased ARV7 expression

Article

作者: Morales, Elisa ; Handle, Florian ; Kremer, Anika ; Peřina, Miroslav ; Kristiansen, Glen ; Van Goubergen, Jasper ; Schmidt, Oliver ; Santer, Frédéric R. ; Cronauer, Marcus V.

In advanced prostate cancer (PC), in particular after acquisition of resistance to androgen receptor (AR) signaling inhibitors (ARSI), upregulation of AR splice variants compromises endocrine therapy efficiency. Androgen receptor splice variant‐7 (ARV7) is clinically the most relevant and has a distinct 3′ untranslated region (3′UTR) compared to the AR full‐length variant, suggesting a unique post‐transcriptional regulation. Here, we set out to evaluate the applicability of the ARV7 3′UTR as a therapy target. A common single nucleotide polymorphism, rs5918762, was found to affect the splicing rate and thus the expression of ARV7 in cellular models and patient specimens. Serine/arginine‐rich splicing factor 9 (SRSF9) was found to bind to and increase the inclusion of the cryptic exon 3 of ARV7 during the splicing process in the alternative C allele of rs5918762. The dual specificity protein kinase CLK2 interferes with the activity of SRSF9 by regulating its expression. Inhibition of the Cdc2‐like kinase (CLK) family by the small molecules cirtuvivint or lorecivivint results in the decreased expression of ARV7. Both inhibitors show potent anti‐proliferative effects in enzalutamide‐treated or ‐naive PC models. Thus, targeting aberrant alternative splicing at the 3′UTR of ARV7 by disturbing the CLK2/SRSF9 axis might be a valuable therapeutic approach in late stage, ARSI‐resistant PC.

2023-04-06·bioRxiv : the preprint server for biology

Combination CDC-like kinase inhibition (CLK)/Dual-specificity tyrosine-regulated kinase (DYRK) and taxane therapy in CTNNB1-mutated endometrial cancer.

作者: Woodruff, Elizabeth ; Corr, Bradley R ; Wolsky, Rebecca J ; Watson, Zachary L ; Jordan, Kimberly R ; Danhorn, Thomas ; Bitler, Benjamin G ; Bailey, Courtney ; Moroney, Marisa R

SM08502 (cirtuvivint) is a novel pan CDC-like kinase (CLK) and Dual specificity tyrosine kinase (DYRK) inhibitor that targets mRNA splicing and is optimized for Wnt pathway inhibition. Previous evaluation of single agent CLK/DYRK inhibition (SM04690) demonstrated inhibition of tumor progression and β-catenin/TCF transcriptional activity in CTNNB1-mutant endometrial cancer (EC). In-vitro analysis of SM08502 similarly decreases Wnt transcriptional activity and cellular proliferation while increasing cellular apoptosis. SM08502 is an active single-agent therapy with IC50's in the nanomolar range for all EC cell lines evaluated. Combination of SM08502 with paclitaxel has synergistic effect in vitro, as demonstrated by Combination Index <1, and inhibits tumor progression in four endometrial cancer models (HEC265, Ishikawa, Ishikawa-S33Y, and SNGM). In our in vivo mouse models, Ishikawa demonstrated significantly lower tumor volumes of combination vs SM08502 alone (Repeated Measures one-way ANOVA, p = 0.04), but not vs paclitaxel alone. HEC265, SNGM, and Ishikawa-S33Y tumors all had significantly lower tumor volumes with combination SM08502 and paclitaxel compared to single-agent paclitaxel (Repeated Measures one-way ANOVA, p = 0.01, 0.004, and 0.0008, respectively) or single-agent SM08502 (Repeated Measures one-way ANOVA, p = 0.002, 0.005, and 0.01, respectively) alone. Mechanistically, treatment with SM08502 increases alternative splicing (AS) events compared to treatment with paclitaxel. AS regulation is an important post-transcriptional mechanism associated with the oncogenic process in many cancers, including EC. Results from these studies have led to a Phase I evaluation of this combination in recurrent EC.

项与 Cirtuvivint 相关的新闻（医药）

2025-05-01

·GlobeNewswire-Health Care

Biosplice Announces First Patient Dosed in Phase 2 Trial of Cirtuvivint for Advanced Soft-Tissue Sarcomas

Multicenter study sponsored by SELNET to evaluate cirtuvivint as a second-line monotherapy in selected sarcoma subtypesSAN DIEGO, May 01, 2025 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases, today announced that the first patient has been dosed in a Phase 2 clinical trial evaluating cirtuvivint in patients with advanced soft-tissue sarcomas. The multicenter, open-label trial, led by Principal Investigator Dr. Javier Martin Broto, is sponsored by SELNET (Sarcoma European and Latin American Network) and is being conducted at eight clinical sites across Spain. This Investigator Initiated Trial follows a preclinical collaboration and focuses on specific sarcoma subtypes, aiming to assess the safety and efficacy of cirtuvivint as a monotherapy. SELNET elected to sponsor the trial following a comprehensive review of preclinical data, which demonstrated compelling activity of cirtuvivint across multiple soft-tissue sarcoma cell lines and xenograft models that were refractory to other treatments. The “Multicenter, Open-Label Phase 2 Trial of Cirtuvivint as a Second-Line Therapy in Selected Advanced Soft-Tissue Sarcomas" will evaluate cirtuvivint monotherapy in approximately 30 patients whose disease has progressed following initial standard of care. The trial focuses on specific sarcoma subtypes and aims to assess the safety and efficacy of cirtuvivint in this difficult-to-treat patient population. “This trial represents a critical step forward for patients with advanced soft-tissue sarcomas, who currently face limited therapeutic options after first-line treatment,” said Dr. Yusuf Yazici, Chief Medical Officer of Biosplice. “We are grateful to SELNET and the participating investigators for their partnership in evaluating cirtuvivint in this patient population. Cirtuvivint has shown compelling activity in preclinical sarcoma models, and this study is a key milestone in our efforts to bring new therapeutic options to patients with high unmet need.” Soft-tissue sarcomas (STS) are a heterogeneous group of rare cancers originating in connective tissues, and treatment-resistant forms of the disease remain a significant challenge. Biosplice is exploring cirtuvivint’s utility across multiple tumor types based on its unique mechanism of action and encouraging safety and pharmacokinetic profile observed in earlier studies. Additional information about the study can be found on euclinicaltrials.eu, EUCT 2024-511987-10-00. About Biosplice:Biosplice stands at the forefront of research concentrating on the study and regulation of Cdc2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs). These kinases play pivotal roles in cell cycle regulation, splicing, and neurodevelopment, marking them as critical targets for therapeutic intervention in a range of diseases, including osteoarthritis, cancer, neurological disorders, and diabetes. With a robust chemical platform for kinase inhibition and a deep understanding of kinase signaling pathways, Biosplice leverages cutting-edge technologies to discover and develop highly selective kinase inhibitors. Biosplice’s drugs in clinical development include lorecivivint for knee osteoarthritis (completed Phase 3) and cirtuvivint for numerous cancers, with a broad preclinical pipeline that encompasses Alzheimer’s disease, diabetes and other degenerative conditions. About Cirtuvivint:Cirtuvivint is a small molecule inhibitor of CLK and DYRK kinases, which are increasingly recognized as key drivers of various cancers. By targeting these kinases, cirtuvivint modulates alternative pre-mRNA splicing, which reduces the expression of genes vital for tumor growth, survival, and drug resistance. The compound has shown broad anti-tumor activity across a range of solid and liquid tumors in extensive preclinical studies. Cirtuvivint has also been investigated for the treatment of advanced solid tumors in two clinical trials. The first, SM08502-ONC-01 (NCT03355066), was a first-in-human dose escalation study designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. The second, SM08502-ONC-03 (NCT05084859), was a Phase 1b trial assessing the efficacy of cirtuvivint in combination with standard treatments for patients with advanced castration-resistant prostate cancer, advanced non-small cell lung cancer, and advanced colorectal cancer. A study sponsored by the National Cancer Institute will explore cirtuvivint in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). About SELNET: The Sarcoma European and Latin American Network (SELNET) is a transnational consortium committed to improving outcomes for patients with sarcomas through collaboration in clinical research, education, and access to innovation across Europe and Latin America. Learn more at https://www.biosplice.com Corporate Contact: Erich Horsley erich.horsley@biosplice.com

临床2期临床1期临床3期临床结果

2024-09-12

·GlobeNewswire-Health Care

Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)

Biosplice expands its clinical candidate, cirtuvivint, as standalone treatment and combination therapy in patients with AML and MDS, representing next step in ongoing collaboration with the NCISAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering advancements in small molecule inhibition of CDC-like kinases (CLK) and Dual-specificity tyrosine phosphorylation-regulated (DYRK) kinases, is pleased to announce that the U.S. Food and Drug Administration (FDA) has cleared the NCI-sponsored Investigational New Drug (IND) application for cirtuvivint. This small molecule inhibitor of CLK and DYRK kinases is in development for the treatment of hematological malignancies and solid tumors. This clearance allows for the initiation of a new clinical trial of cirtuvivint, both as a standalone treatment for patients with relapsed/refractory AML and MDS as well as in combination with ASTX727 for patients with frontline high-risk MDS. The clinical study (NCI protocol 10674, NCT06484062) will be sponsored by the NCI, part of the National Institutes of Health, with Dr. Maximilian Stahl from the Dana-Farber Cancer Institute serving as principal investigator. This trial will be conducted in participating centers of the NCI’s Experimental Therapeutics Clinical Trials Network including Dana-Farber Cancer Institute and Memorial Sloan Kettering Cancer Center. The study aims to enroll up to 52 patients and will be conducted under the Cooperative Research and Development Agreement (CRADA) executed between Biosplice and the NCI. “We are thrilled that the NCI has received FDA clearance to launch this groundbreaking new Phase 1 trial of cirtuvivint in liquid tumors, both as monotherapy and in combination with ASTX727,” stated Dr. Yusuf Yazici, Chief Medical Officer of Biosplice. “This milestone is a major step forward in our efforts to advance innovative treatments targeting CLKs and DYRKs. Given that dysregulated alternative splicing is commonly implicated in AML and MDS, cirtuvivint’s ability to regulate alternative splicing via CLK and DYRK inhibition may provide a promising new therapeutic pathway for patients. Based on compelling anti-tumor activity across both solid and liquid tumors in in vitro and in vivo models, as well as data from two prior Phase 1 trials in solid tumors, cirtuvivint promises to greatly improve outcomes for patients in these critical and underserved areas.” This milestone highlights the ongoing collaboration between Biosplice and the NCI’s Cancer Therapy Evaluation Program (CTEP) through the NCI Experimental Therapeutics (NCI-NExT) program. After extensive evaluation, cirtuvivint was chosen for inclusion by NCI in the NExT programs following a competitive review. NCI-NExT partners with external researchers and leading scientific experts to accelerate the development of the most promising and innovative therapies, guiding them from early-stage research through to regulatory approval. About Biosplice:Biosplice stands at the forefront of research concentrating on the study and regulation of Cdc2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs). These kinases play pivotal roles in cell cycle regulation, splicing, and neurodevelopment, marking them as critical targets for therapeutic intervention in a range of diseases, including osteoarthritis, cancer, neurological disorders, and diabetes. With a robust chemical platform for kinase inhibition and a deep understanding of kinase signaling pathways, Biosplice leverages cutting-edge technologies to discover and develop highly selective kinase inhibitors. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis (completed Phase 3) and cirtuvivint for numerous cancers, with a broad preclinical pipeline that encompasses Alzheimer’s disease, diabetes and other degenerative conditions. About Cirtuvivint:Cirtuvivint is a small molecule inhibitor of CLK and DYRK kinases, which are increasingly recognized as key drivers of various cancers. By targeting these kinases, cirtuvivint modulates alternative pre-mRNA splicing, which may reduce the expression of genes vital for tumor growth, survival, and drug resistance. The compound has shown broad anti-tumor activity across a range of solid and liquid tumors in extensive preclinical studies. Cirtuvivint has also been investigated for the treatment of advanced solid tumors in two clinical trials. The first, SM08502-ONC-01 (NCT03355066), was a first-in-human dose escalation study designed to evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. The second, SM08502-ONC-03 (NCT05084859), was a Phase 1b trial assessing the efficacy of cirtuvivint in combination with standard treatments for patients with advanced castration-resistant prostate cancer, advanced non-small cell lung cancer, and advanced colorectal cancer. Learn more at https://www.biosplice.com

临床1期临床申请临床3期

2024-06-13

·BioSpace

Biosplice Announces Collaboration with Novo Nordisk in Diabetes

Biosplice to leverage leading position in small-molecule DYRK inhibition with Novo Nordisk in a pre-clinical collaboration to develop first-in-class therapies for diabetes. SAN DIEGO, June 13, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering first-in-class therapeutics based on small-molecule inhibition of DYRK/CLK kinases, has entered a collaboration with Novo Nordisk to develop drug candidates for the treatment of diabetes. This agreement builds upon Biosplice’s innovative research, supported by robust external scientific literature, demonstrating the potential of DYRK inhibition to stimulate β-cell proliferation in animal models and human islet cells, thus offering a promising avenue for diabetes treatment. The collaboration combines Novo Nordisk’s expertise in diabetes and Biosplice’s research and development efforts focused on creating selective and potent DYRK inhibitors. Under the terms of the agreement, Novo Nordisk will fund further preclinical development, with an exclusive option to license Biosplice’s relevant intellectual property primarily focused on cardiometabolic disorders. Specific financial terms were not disclosed, but would include upfront and milestone payments plus royalties for the exclusive license. “We are extremely pleased to combine our unique DYRK inhibition expertise with Novo Nordisk’s leadership in diabetes treatments,” commented Erich Horsley, CFO and CBO of Biosplice. “For over a decade, Biosplice has pioneered the therapeutic potential of highly selective, small-molecule inhibition of DYRK and CLK kinases. Representing over 500 million patients worldwide, diabetes sufferers stand to benefit enormously from developing therapies, such as ours, which hold the promise of restoring the health of human β-cells. We eagerly anticipate unlocking the immense possibilities through our collaboration with Novo Nordisk.” Biosplice management believes that its selective DYRK inhibitors, which have shown encouraging results in animal models and human islet cells, promise excellent potency and safety margins to enable a first-in-class therapy for diabetes treatment. Scientific literature suggests that DYRK kinases play a pivotal role in maintaining the proliferative capacity of β-cells, essential pancreatic cells responsible for producing insulin, a critical hormone regulating blood sugar. Diabetes patients grapple with insufficient insulin production due to a deficiency or dysfunction of pancreatic β-cells. This approach could potentially go beyond currently approved therapies to address the underlying cause of the disease. Biosplice will present publicly some of its preclinical findings from in vivo and in vitro models at the upcoming American Diabetes Association’s conference in Orlando, Florida on June 23 at 12:30 pm. The DYRK kinase has also been implicated as a key driver of harmful aggregation of tau protein, a potential driver of serious neurological conditions. Biosplice has recently announced a collaboration with The Roskamp Institute for traumatic brain injury and is developing lead candidates for the treatment of various tauopathies and neuroinflammatory conditions, including Alzheimer’s disease, frontal temporal dementia and multiple sclerosis. About Biosplice’s Diabetes Program: Biosplice pioneers the development of highly selective and potent DYRK inhibitors to stimulate insulin-secreting β-cell proliferation, a crucial advancement in diabetes treatment. Targeting DYRK holds immense potential in enhancing pancreatic islet function and refining glucose regulation, addressing a key shortfall in both type 1 and type 2 diabetes management. Biosplice's compounds have shown promising results in animal models and human islet cells, amplifying β-cell regeneration and offering renewed hope for effective diabetes therapies. About Biosplice Biosplice stands at the forefront of research concentrating on the study and regulation of Cdc2-like kinases (CLKs) and dual-specificity tyrosine-regulated kinases (DYRKs). These kinases play pivotal roles in cell cycle regulation, splicing, and neurodevelopment, marking them as critical targets for therapeutic intervention in a range of diseases, including osteoarthritis, cancer, neurological disorders, and diabetes. With a robust chemical platform for kinase inhibition and a deep understanding of kinase signaling pathways, Biosplice leverages cutting-edge technologies to discover and develop highly selective kinase inhibitors. Biosplice’s drugs in clinical development include lorecivivint for osteoarthritis and cirtuvivint for numerous cancers, with a broad pre-clinical pipeline that encompasses Alzheimer’s disease, diabetes and other degenerative conditions. Learn more at Corporate Contact: Erich Horsley erich.horsley@biosplice.com

引进/卖出

100 项与 Cirtuvivint 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
小细胞肺癌	临床2期	美国	Biosplice Therapeutics, Inc.	2025-12-31
X联锁鱼鳞病	临床2期	西班牙	Biosplice Therapeutics, Inc.	2025-01-15
局部晚期软组织肉瘤	临床2期	西班牙	Biosplice Therapeutics, Inc.	2025-01-15
复发性急性白血病	临床1期	美国	National Cancer Institute	2025-12-15
复发性骨髓增生异常综合征	临床1期	美国	National Cancer Institute	2025-12-15
难治性急性髓细胞白血病	临床1期	美国	National Cancer Institute	2025-12-15
难治性骨髓增生异常综合征	临床1期	美国	National Cancer Institute	2025-12-15
乳腺癌	临床1期	美国	University of Colorado Denver	2025-12-01
卵巢子宫内膜样癌	临床1期	美国	University of Colorado Denver	2025-12-01
输卵管癌	临床1期	美国	University of Colorado Denver	2025-12-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05084859 \| NCT03355066 (ESMO2022) 人工标引	临床1期	晚期恶性实体瘤 \| 非小细胞肺癌 \| 结直肠癌 ... ARV7 Positive 更多	65	cirtuvivint+abiraterone acetate+FOLFIRI-panitumumab/docetaxel	餘廠夢齋鹹製齋齋鬱遞(繭窪構構製鬱遞繭衊窪) = 壓艱窪襯夢簾膚觸觸鏇淵壓構夢衊淵積鑰窪襯 (鑰膚觸鑰糧鏇鹹糧窪糧 ) 更多	积极	2022-09-10
NCT03355066 (FIH（Biosplice）, AACR 12021 \| AACR 22021) 人工标引	临床1期	晚期恶性实体瘤	19	SM08502	蓋簾衊鏇遞願鑰鏇網壓(壓糧衊築製襯衊築鑰膚) = diarrhea (2/19 [10.5%]) 醖積選選構窪製鏇選膚 (糧齋簾遞襯窪選壓齋齋 ) 更多	积极	2021-07-01
NCT03355066 (AACR2020)	临床1期	去势抵抗性前列腺癌	82	SM08502	蓋夢觸構鏇廠網夢膚願(憲鹽獵遞鏇鹹網製積繭) = 膚範齋壓顧製憲築構淵襯艱獵遞遞餘鏇觸蓋鑰 (襯製壓鏇淵糧鏇壓襯鹹 ) 更多	-	2020-08-15
NCT03355066 (AACR2020)	临床1期	去势抵抗性前列腺癌	82	Abiraterone	蓋夢觸構鏇廠網夢膚願(憲鹽獵遞鏇鹹網製積繭) = 淵窪鹽願積艱艱壓憲觸襯艱獵遞遞餘鏇觸蓋鑰 (襯製壓鏇淵糧鏇壓襯鹹 )	-	2020-08-15
NCT03355066 (AACR2020)	临床1期	HR阳性乳腺癌	82	SM08502	獵壓膚簾鹽艱淵襯鬱遞(積鏇簾築糧淵鏇積淵遞) = 繭醖艱餘願齋繭鹽鏇壓醖觸襯憲夢鬱範構憲夢 (製鏇鑰簾製築廠膚鹹顧, <0.001)	-	2020-08-15
NCT03355066 (AACR2020)	临床1期	HR阳性乳腺癌	82	Fulvestrant	獵壓膚簾鹽艱淵襯鬱遞(積鏇簾築糧淵鏇積淵遞) = 淵衊築襯鑰製選製鬱製醖觸襯憲夢鬱範構憲夢 (製鏇鑰簾製築廠膚鹹顧, 0.34)	-	2020-08-15
NCT03355066 (P3-13-01, SABCS2020)	临床1期	三阴性乳腺癌	-	SM08502	艱淵築鏇憲鹹積醖鹹製(衊製鏇範獵鬱壓簾衊鹽) = 網廠製築糧選積製蓋醖糧壓窪網廠窪醖簾願襯 (繭鹹網範憲積齋壓襯願, 0.055 ~ 0.510) 更多	-	2020-02-15
NCT03355066 (P3-13-01, SABCS2020)	临床1期	三阴性乳腺癌	-	Gemcitabine (G)/Nab-paclitaxel (Nab-P)	網構艱選艱鹽糧窪廠糧(憲蓋鬱淵憲鹹襯觸繭餘) = 鑰鹹觸廠鑰衊窪衊簾繭遞廠願繭壓鏇選齋顧構 (獵鹹鏇衊膚糧願鹹積觸 )	-	2020-02-15
NCT03355066 (ASCO2019)	临床1期	结直肠癌	82	SM08502	醖積醖夢餘選衊顧範製(淵廠襯積餘衊醖壓襯壓) = 糧齋簾糧築鹽簾鹹願鹹遞糧醖選醖襯夢窪餘壓 (醖築構積範淵襯廠繭鹹 ) 更多	-	2019-05-26